The FDA draft guidance on container closure systems published in August 2026 rewrites, after more than twenty-five years, the US reference for the quality of packaging systems for drugs and biologics. The draft, issued jointly by CDER and CBER, is intended to supersede the historic May 1999 guidance "Container Closure Systems for Packaging Human Drugs and Biologics" and the May 2002 Questions & Answers document. For anyone working in QA, pharmaceutical development or regulatory affairs, now is the time to understand what changes: the public comment period closed on October 13, 2026, and the final version is expected once the comments have been reviewed.
What the new FDA draft guidance on container closure systems covers
The roughly 37-page document sets out the principles the Agency will use to assess the quality of container closure systems (CCS) in marketing applications, amendments and supplements. Compared with 1999, the scope widens considerably: the draft also covers CCSs that are device constituent parts of combination products (for example prefilled syringes and autoinjectors), bulk containers, newer packaging systems, and even OTC products marketed under section 505G of the FD&C Act, i.e. without an approved application. It also introduces a dedicated section on classifying postapproval changes to the CCS and the related reporting obligations.
The underlying approach is explicitly risk-based, consistent with ICH Q9(R1): the depth of the evaluation must be proportionate to the product, the closure system and its intended use. A CCS suitable for one product is not automatically suitable for another: the demonstration of suitability remains specific to each product-packaging combination.
The risk-based framework: which dosage forms carry the most risk
The operational core of the draft is the table ranking dosage forms along two dimensions: the criticality of the route of administration and the likelihood of drug-packaging interaction. The logic follows 1999 but is updated and made explicitly illustrative: even low-risk forms still require a documented assessment.
| Risk level | Dosage forms | Expected scrutiny |
|---|---|---|
| Highest | Inhalation products (propellant-based MDIs have the highest interaction risk) | Full evaluation, in-depth E&L |
| High | Transdermal systems, nasal propellant aerosols, ophthalmic and otic products | Extensive compatibility studies |
| Medium | Injectables (higher risk with excipients or organic solvents), nasal sprays, topical dermal products | Targeted E&L, CCI for sterile products |
| Lower | Solid oral forms; oral solutions and suspensions carry higher risk than solids | Proportionate but documented assessment |
For each CCS, the suitability evaluation is built on the four classic attributes, now detailed with greater technical precision: protection (light, moisture, reactive gases, solvent loss and container closure integrity), compatibility, safety (extractables & leachables, biocompatibility, particulate matter) and performance (functionality of the assembled system and drug delivery).
Topics like this move fast: between drafts, comments and final versions it is easy to miss the step that matters. Every week The Pragmatic GMP, GuideGxP's free newsletter, selects the regulatory updates that really matter for QA and QC and turns them into concrete actions: subscribe so you never have to chase the next guidance.
The most significant technical changes versus the 1999 guidance
Several points in the draft deserve a targeted gap analysis, because they touch long-established practice:
- CCIT instead of sterility testing: for sterile products FDA expresses a clear preference for container closure integrity testing (deterministic, in line with USP <1207>) over sterility testing in stability programs, including integrity checks at extreme temperatures.
- Leachables across the whole shelf life: leachables studies should normally be run on three batches in formal stability studies, with toxicological evaluation of compounds above the qualification threshold and a proposed safety concern threshold of 1.5 mcg/day for most chronic-use products.
- Shipping stress and cold chain: the draft spells out expectations on freeze-thaw, thermal cycling and shipping validation as part of demonstrating CCS suitability.
- Recycled plastic: a restriction is introduced on the use of postconsumer recycled plastic in primary packaging.
- Anchoring to USP chapters: the text systematically references compendial chapters, including USP <381>, <660>, <661>, <661.1>, <661.2>, <670>, <671>, <1207>, <1663> and <1664>.
FDA also announces further topic-specific guidances, including the characterization of novel closure systems and deeper coverage of extractables & leachables with the associated toxicological assessment, while ICH Q3E on the same topic is under development internationally.
Combination products and bulk containers: a wider scope
One of the most awaited extensions concerns combination products: where the CCS is also the device constituent part of the product (prefilled syringes, pens, autoinjectors), the draft asks sponsors to demonstrate not only protection and compatibility but also the functionality of the assembled system and consistency with the applicable design requirements, referencing 21 CFR Part 4 and ISO 13485:2016. Bulk containers for intermediates and finished product, and the information to be provided in the different application types, master files included, also come explicitly into scope. This is a step change from 1999, when these scenarios were handled piecemeal or deferred to other documents.
What it means for sites exporting to the US
For European companies registering or manufacturing for the US market, the draft is a credible preview of the questions that will arrive in quality reviews and inspections: read it as a checklist of what FDA reviewers will expect to find in Module 3. Typical mistakes to avoid: treating CCS qualification as a one-off exercise closed during development; reusing a suitability dossier from one product on another without a specific risk assessment; treating E&L as a parenteral-only topic, when the framework grades it across all dosage forms; and forgetting that postapproval packaging changes now have a more structured reporting pathway.
GuideGxP recommendation
Our practical advice is not to wait for the final version: start a gap assessment of your CCS dossiers against the draft now, beginning with the highest-risk products (inhalers, transdermals, ophthalmics, parenterals with critical solvents or excipients). Verify that your CCIT strategy is deterministic and consistent with USP <1207>, that leachables studies cover the shelf life on stability batches, and that toxicological evaluations are documented with justified thresholds. Finally, align your packaging change control with the new postapproval reporting categories.
To structure this work, the GuideGxP guide Extractables & Leachables and USP <381>/<382> for parenterals covers risk-based qualification of the closure system according to USP, ICH Q3E and the new FDA draft guidance, with a ready-to-use toolkit.
